Madison, Wisconsin (WMTV)-This competition will continue to test and find the first effective COVID-19 vaccine, and the cell and gene product development facility at Western Michigan University-Madison is helping to produce the vaccine.
Wisman Biomanufacturing Corporation announced on Monday that they will collaborate with Heat Biologics to produce vaccines for phase 1 and phase 2 clinical trials.
They expect the first phase of the trial may begin in early 2021, and the University of Wisconsin-Madison may become the test site.
Jeff Wolf, CEO of Heat Biologics, said: “In addition to its potential as a stand-alone COVID-1
The vaccine uses a genetically engineered combination of common proteins found in human cells and viral proteins to generate a response from human T cells, thereby helping immunity.
The vaccine will target people most vulnerable to the virus, including the elderly and people with compromised immune systems.
“The mission of Waisman Biomanufacturing is to promote new vaccines and therapeutics to early human clinical trials,” said Carl Ross, managing director of Waisman Biomanufacturing, part of the Waisman Center. “We are very happy to provide what we need for this cause.”
According to Brian Dattilo, business development manager of Waisman Biomanufacturing, the manufacturer will provide development and engineering technology for Heat Biologics.
The company will also produce clinical batches of vaccines.
Waisman Biomanufacturing previously collaborated with Heat Biologics to develop two cancer vaccines, one of which is in phase 2 clinical trials. The other completed the registration for the second phase of the trial.
Wisman Biological Manufacturing Co., Ltd. was established in 2001. It is part of the Wisman Center.
Copyright WMTV 2020. all rights reserved.